AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02559258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Study NCT00661856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
Study NCT03356756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: simultaneous combined 18F-FDG PET and cardiac MRI imaging
Description: Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
Study NCT01506258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of Stem Cells
Description: IV infusion of autologous stem cells within the first 48 hours after birth.
Study NCT01506258 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Observation
Description: Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
Study NCT01957774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-18
Description: THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
Study NCT01957774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01497431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Given PO
Study NCT01497431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01497431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01497431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01497431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02559258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Study NCT01497431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02559258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 60 minutes
Study NCT02559258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 120 minutes
Study NCT02600442 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Study NCT01497431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Given PO
Study NCT04163458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL
Description: Solution for injection in pre-filled pen, subcutaneous administration
Study NCT04163458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MENOPUR powder and solvent for solution for injection, 75 IU
Description: Solution for injection in vials (powder and diluent), subcutaneous administration
Study NCT04163458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for MENOPUR solution for injection in pre-filled pen)
Description: Solution for injection in pre-filled pen, subcutaneous administration
Study NCT04163458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (for MENOPUR powder and solvent for solution for injection)
Description: Solution for injection in vials (powder and diluent); subcutaneous administration
Study NCT02092844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Menopausal Insomnia (CBTMI)
Description: Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
Study NCT02092844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT for Menopausal Insomnia (CBTMI)
Description: Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
Study NCT00079482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEP-701
Study NCT00079482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose cytarabine
Description: Chemotherapy
Study NCT04423276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
Study NCT00079482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
Description: Chemotherapy
Study NCT00607503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly.
Study NCT04574284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT04574284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study NCT03316430 — intervention group
Intervention type: OTHER
Intervention: Podocyturia quantification
Description: Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
Study NCT01524744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus ointment
Description: Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
Study NCT01524744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adcortyl
Description: triamcinolone acetonide 0.1% in orabase
Study NCT03770286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Fluoride Varnish
Description: Topical varnish
Study NCT03770286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Fluoride Varnish
Description: Topical varnish
Study NCT03068637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carevive CPS
Description: This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
Study NCT00855153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR (Virtual reality)
Description: VR stimulation of combat scenarios utilized as the exposure therapy tool.
Study NCT03770286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 38% Silver diamine fluoride
Description: Topical varnish
Study NCT04423276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study NCT00855153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
Study NCT03101618 — intervention group
Intervention type: OTHER
Intervention: Animal allergy
Description: Allergic symptom occurs during exposure to laboratory or pet animal
Study NCT03101618 — intervention group
Intervention type: OTHER
Intervention: Non-animal allergy
Description: Allergic symptom does not occur during exposure to laboratory or pet animal
Study NCT03770286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super Floss
Description: Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
Study NCT04308746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Individualistic Prime (statement writing)
Description: Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
Study NCT04308746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Collectivistic Prime (statement writing)
Description: Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
Study NCT01899872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Description: Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
Study NCT01899872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session
Description: Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
Study NCT03582618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
Study NCT03582618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
Study NCT02177851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single oral iron dose of 120 mg per day for 3 consecutive days
Study NCT02177851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
Study NCT01671241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene wrap
Study NCT01671241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene wrap
Study NCT02615535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback-assisted meditation
Description: meditation with auditory feedback regarding EEG status
Study NCT03379870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting
Description: Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
Study NCT04395079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04395079 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT04395079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03868111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Study NCT03868111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Study NCT01629537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block injection with ropivicane
Description: For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
Study NCT01629537 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo Procedure
Description: In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
Study NCT00862537 — intervention group
Intervention type: DEVICE
Intervention: Resonator Device
Description: active pico-tesla magnetic fields treatment for Parkinson's disease individuals
Study NCT04290234 — intervention group
Intervention type: OTHER
Intervention: fMRI assessment of cognitive and reactive fear
Description: An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
Study NCT01062334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Microdialysis, CT-scan, leakage scoring
Description: Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
Study NCT01531504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ViKY UP
Description: laparoscopic-assisted hysterectomy procedure
Study NCT03367936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Session
Description: Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
Study NCT03367936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one Session
Description: Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
Study NCT03367936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Participants will receive an orientation on how to self-monitor using the smartphone and other devises
Study NCT03367936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will receive an orientation on how to self-monitor using the smartphone and other devises
Study NCT03367936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
Study NCT03863041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional sequence performed during MRI scan
Description: An additional sequence will be performed during the MRI scan.
Study NCT01348204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quercetin
Description: health food supplement
Study NCT01017094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silversulfadiazine
Description: apply once a day
Study NCT04615533 — intervention group
Intervention type: OTHER
Intervention: Frail older adults, assessment
Description: Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
Study NCT00747331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesilate
Description: Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
Study NCT00747331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug
Study NCT01553383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal peep valve Provent
Description: application of nasal peep valve vs dental device and cpap
Study NCT03289858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Subcutaneous injection at conclusion of surgical fixation of hip fracture
Study NCT03289858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Saline Injection
Study NCT00839722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: fertility after embolization
Study NCT02201849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drug
Study NCT02201849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Study NCT02201849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01501370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
Study NCT01501370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
Study NCT01501370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
Study NCT01501370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
Study NCT01501370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
Study NCT03643575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicks Cough Syrup for Chesty Coughs
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Study NCT03643575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Robitussin Extra Strength Chest Congestion
Description: Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Study NCT03643575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Organ-I- NR tablet
Description: Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
Study NCT02824575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: 50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study NCT02824575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study NCT02824575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study NCT01000402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psychopharmacotherapy
Description: Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
Study NCT02183896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Study NCT02183896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT05393011 — intervention group
Intervention type: DRUG
Intervention: human chorionic gonadotropin
Description: 10000 IU when at least three follicles become more than 16 mm